Adult B-lymphoblastic leukemia (B-ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with classical chemotherapeutics and novel targeted agents, enduring remission is often hampered by disease relapse due to outgrowth of a pre-existing subclone resistant against the treatment. In this study, we show that small glycophosphatidylinositol (GPI)-anchor deficient CD52-negative B-cell populations are frequently present already at diagnosis in B-ALL patients, but not in patients suffering from other B-cell malignancies. We demonstrate that the GPI-anchor negative phenotype results from loss of mRNA expression of the PIGH gene, which is involved in the first step of GPI-anchor synthesis. Loss of PIGH mRNA expression within these B-ALL cells follows epigenetic silencing rather than gene mutation or deletion. The coinciding loss of CD52 membrane expression may contribute to the development of resistance to alemtuzumab (ALM) treatment in B-ALL patients resulting in the outgrowth of CD52-negative escape variants. Additional treatment with 5-aza-2 0 -deoxycytidine may restore expression of CD52 and revert ALM resistance.
single drug treatment for B-ALL resulted in only modest clinical efficacy. Despite similarly high membrane expression of the glycophosphatidylinositol (GPI)-anchored ALM target antigen CD52 across all the B-ALL molecular subtypes (with t(4;11) as the only exception), 7 only a minority of the patients achieved an enduring complete remission due to early relapses. 8, 9 This could be the result of outgrowth of CD52-negative B-ALL escape variants, 10, 11 as demonstrated in a mouse model engrafted with human B-ALL. 10 These CD52-negative B-ALL cells displayed normal CD52 gene expression, but remarkably loss of CD52 membrane expression coincided with loss of other GPI-linked proteins like CD55 and CD59, indicating that loss of GPI-anchor expression had been the underlying cause. This loss of GPI-anchor expression was not the result of mutations in the X-linked PIGA gene, 10 one of 28 genes essential for GPI-anchor synthesis, 12 which causes loss of GPI-anchor expression in paroxysmal nocturnal hemoglobinuria (PNH). 13, 14 The aim of this study was to unravel the mechanisms underlying loss of GPI-anchor expression and coinciding loss of CD52 membrane expression in B-ALL. We show that small pre-existing GPI/CD52-negative B-cell populations are frequently present in peripheral blood (PB) and bone marrow (BM) of B-ALL patients already at diagnosis, but not in patients suffering from other B-cell malignancies or in healthy donor B cells. We demonstrate that loss of mRNA expression of the PIGH gene, which is involved in the first step of GPI-anchor synthesis, was the underlying cause of loss of GPI-anchor expression in B-ALL cells. This loss of PIGH mRNA expression was not due to genetic aberrations, but rather due to epigenetic silencing. These data describe a new mechanism of loss of GPI-anchor expression. The resulting loss of CD52 membrane expression may confer ALM resistance to B-ALL patients due to the outgrowth of CD52-negative escape variants.
| MATERIALS AND METHODS

| Patient samples
Residual BM or PB samples from ALM-naïve patients with B-ALL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), or mantle cell lymphoma (MCL) which were taken at diagnosis and stored anonymously were used for this study. Mononuclear cells (MNC) were isolated by Ficoll-Isopaque separation and cryopreserved in Iscove's Modified Dulbecco's Media (IMDM, Lonza, Verviers, Belgium) supplemented with 25% fetal calf serum (FCS, Lonza) and 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich, Zwijdrecht, The Netherlands). MNC isolated from PB of healthy donors were taken as control. The use of these materials for research was approved by the Leiden University Medical Center medical ethical committee.
For one patient (ALL-06), a PB sample taken 1 month after relapse that occurred after ALM-treatment was available. In this patient, successful ALM-treatment, as indicated by the absence of circulating lymphocytes 2 months after treatment initiation, was followed by an early relapse at month 4.
| Flow cytometry and cell sorting
GPI-anchor expression was analyzed by flow cytometry on thawed MNC samples stained with the GPI-anchor specific inactivated toxin pro-aerolysin coupled to AlexaFluor488 (FLAER-ALX488, Sanbio, Uden, The Netherlands), allophycocyanin (APC)-conjugated anti-CD52
(ITK diagnostics, Uithoorn, The Netherlands), anti-CD3-phycoerythrin/ cyanine7 (ITK) or anti-CD3-PacificBlue (BD, Becton Dickinson, Breda,
The Netherlands), and phycoerythrin (PE)-conjugated anti-CD19
(BD) and analyzed on an LSRII (BD) (gating strategy in Supporting
Information Figure S1 ). Samples containing FLAER-negative cells, were further characterized by staining with FLAER, anti-CD45-PE (BD), and anti-CD19-APC (BD). FACS-sorting was performed using the same antibodies on a FACSARIA III (BD).
| Fluorescent in situ hybridization analysis
High-resolution karyotype analysis on primary B-ALL samples was performed by combined binary ratio labeling fluorescent in situ hybridization as described before. 15 Fluorescent in situ hybridization analysis specific for cytogenetic aberrations t [9;22] and del7q on FACS-sorted GPI-anchor negative (FLAER-) malignant B cells (CD19 +/CD45dim) was performed using Vysis probe combinations LSI BCR/ABL ES and D7S486/CEP 7 (both Abbott Molecular, Des
Plaines, IL), respectively.
| Expression analysis of GPI-anchor synthesis pathway genes
For each patient sample, equal numbers of GPI-anchor negative and positive B cells (range 3000-670 000 cells) were isolated from thawed MNC samples by FACS-sorting. mRNA was isolated using the RNAqueous-Micro Kit (Thermo Fisher scientific, Bleiswijk, The Netherlands), which included DNAse treatment, quantified using a spectrophotometer (ND-1000, Thermo Fisher scientific), and completely converted to cDNA using M-MLV transcriptase (Thermo Fisher) and oligo-dT primers. cDNA input was equalized for the different samples using the mRNA Nanodrop measurements as reference (minimum of 6 ng of converted mRNA per sample). PCR amplification was performed using specific primers for the 28 GPI-anchor synthesis genes (Supporting Information Table S1 ) and PWO SuperYield DNA polymerase with a touchdown protocol which consisted of initial denatur- Expression analysis of the full protein coding region of PIGH was performed by amplification using specific primers (Supporting Information final extension step at 72 C (7 min). As cDNA loading control, GAPDH was amplified.
| Cell culture conditions and generation of subcultures
Cell lines Leiden-ALL-BV and Leiden-ALL-HP were generated previously in our laboratory from primary B-ALL cells. 15 Retroviral transduction was performed as described before. 2.7 | PIGH mRNA expression and mutational analysis mRNA was isolated from 5.0 × 10 5 cells and partial PIGH transcription variants were amplified by PCR using specific primers (Supporting Information Table S2 ) and Phusion Flash High-Fidelity PCR Master Mix using the protocol described above.
For mutational analysis, DNA was isolated from 2.0 × 10 6 cells using the Gentra Puregene Cell Kit (Qiagen, Venlo, The Netherlands).
Amplification of the 10 kb PIGH genomic region was performed using specific primers (Supporting Information and a final extension step at 72 C (7 min). Products from the nested PCR's were analyzed for mutation in the promoter region, exon boundaries, and gene body by Sanger sequencing using the same primers. All Sanger sequencing was performed by Baseclear (Leiden,
The Netherlands) and analyzed using Geneious 8 software (Biomatters limited, Auckland, New Zeeland). , and HP GPI neg was isolated using an RNAqueous Total RNA Kit (Thermo Fisher scientific), cleaned using an RNeasy mini kit (Qiagen), and quality checked using Agilent RNA6000 chips and the Agilent Bioanalyser (Santa Clara, CA, USA). RNA was amplified using the TotalPrep RNA amplification kit (Ambion). Samples were analyzed using a whole-genome gene expression direct hybridization assay with Human HT-12 v4 Expression BeadChips on a BeadArray 500GX device (all Illumina, San Diego, CA). Data was analyzed using R 2.15 as described before. 17 
| Microarray analysis
| ChIP-qPCR
Chromatin immunoprecipitation (ChIP) was performed as described before. 18 For each subculture 100 × 10 6 cells were fixed using 1% SDS). All samples were reverse cross-linked by overnight heating at 65 C. DNA was purified using phenol-chloroform extraction. DNA was quantified using a ND-1000 spectrophotometer.
Per condition, 5 ng of DNA was analyzed in duplicate by qPCR using specific primers targeting PIGH (Supporting Information 
| Promoter methylation analysis
DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen) and 1 μg was bisulfite-converted using the EZ DNA Methylation Kit (Zymo Research, Orange, CA). Amplification and methylation specific melting curve analysis (MS-MCA) was performed by using specific primers (Supporting Information Table S2) 3 | RESULTS
| Demethylation assay
| GPI/CD52-deficient cells are commonly present in B-ALL, but not in other B-cell malignancies
To examine whether pre-existing populations of GPI/CD52-negative malignant B cells were already present at diagnosis in patients with B-ALL who had not previously received ALM-treatment, we screened primary PB (n = 13) or BM (n = 12) samples from 25 patients with B-ALL who carried various cytogenetic aberrations (Table 1 ). In 13/22 evaluable samples (both PB and BM) clear (>0.025%) GPI-anchor negative populations (median 0.25%) were detected within the B-cell compartment (representative examples in Figure 1 ; aggregated result in Table 1 ). These GPI-anchor negative B cells consistently lacked CD52 Figure S5 ).
For one patient (ALL-06), material taken at diagnosis and material of the relapse that occurred after ALM-treatment was available for
analysis. An enlarged GPI/CD52-negative B-cell population (32.5%)
was found in the sample taken 1 month after relapse (Supporting Information Figure S6 ).
These data demonstrate that the presence of GPI/CD52-negative B-cells is a frequent event in B-ALL, but not in other B-cell malignancies and in healthy donor B cells.
| Loss of PIGH mRNA expression in GPI-anchor negative primary B-ALL cells
To unravel the underlying mechanism resulting in GPI-anchor deficiency within GPI/CD52-negative B-ALL cells, we performed mRNA Figure S3 ). These data show that loss of PIGH mRNA expression is a common phenomenon and associated with the GPI-anchor negative phenotype in B-ALL cells.
| GPI-anchor expression is restored by enforced PIGH expression
To assess whether absence of PIGH mRNA expression was the sole cause of the GPI-anchor negative phenotype in B-ALL cells, we restored PIGH expression by retroviral transduction. We used cell lines Leiden-ALL-BV and Leiden-ALL-HP which were generated from primary B-ALL cells of samples ALL-02 and ALL-06 (after relapse following ALM-treatment), respectively. These cell lines contained 10.4%
(Leiden-ALL-BV) and 0.4% (Leiden-ALL-HP) GPI-anchor negative cells.
GPI-anchor negative and GPI-anchor positive subpopulations were purified by FACS-sorting (Supporting Information Figure S7 ). The GPIanchor phenotype of these subcultures was stable during culturing.
Absence of PIGH mRNA within GPI-anchor negative, but not within GPI-anchor positive subcultures was shown by mRNA expression analysis (Supporting Information Figure S8 ). In contrast, identical transcriptional activity was observed between the GPI-anchor negative and positive subcultures for the remaining GPI-anchor synthesis genes (Supporting Information Figure S9 ). High levels of CD52 mRNA were present in both the GPI-anchor negative and positive subcultures (Supporting Information Figure S9 ). Restored GPI-anchor and coinciding CD52 membrane expression was observed in the GPI-anchor negative subcultures upon retroviral transduction with a construct encoding PIGH, but not with PIGA or a mock construct (Figure 2A ). In the GPI-anchor positive subcultures no effect on GPI-anchor or CD52 membrane expression was observed upon transduction ( Figure 2B ).
In conclusion, the GPI-anchor negative phenotype in B-ALL cells was solely mediated by absence of PIGH mRNA expression.
| Loss of PIGH mRNA expression does not result from a genetic aberration
To investigate if genetic aberrations resulted in loss of PIGH mRNA expression in GPI-anchor negative B-ALL cells, we first tested whether the inability to detect PIGH mRNA expression in the GPIanchor negative subcultures of the Leiden-ALL-BV and -HP cell lines was the result of loss of a primer binding site due to alternative splicing of the pre-mRNA. We performed PCR specific for sections of PIGH mRNA that include all possible transcription variants ( Figure 2C , amplicons i-iv). No amplicons were generated for the GPI-anchor negative subcultures, whereas all amplicons were generated for the GPIanchor positive subcultures ( Figure 2D ). This shows that inability to detect PIGH mRNA in GPI-anchor negative subcultures was due to complete absence of PIGH mRNA expression.
To examine if loss of PIGH mRNA expression in the GPI-anchor negative subcultures resulted from genomic deletion of PIGH, we performed PCR using primers designed to amplify the complete 10 kb Figure S10 ).
To investigate if a mutation, small deletion, or insertion in the promoter region (starting 630 bp before the transcription start site), at one of the splice sites, or in the gene body was the cause of loss of PIGH mRNA expression, we examined these genetic loci by Sanger sequencing ( Figure 2C , amplicons vii-x). No differences in DNA sequences were found between the GPI-anchor negative and positive subcultures. Within each amplicon, at least one known SNP was identified for which both allelic variants were detected (data not shown).
These SNPs were always detected in both the GPI-anchor negative and positive subcultures, indicating that each analyzed amplicon originated from both alleles of the PIGH gene.
In summary, the intact PIGH gene was present in both GPI-anchor negative B-ALL subcultures, illustrating that loss of PIGH expression in these cells could not be explained by obvious genetic aberrations in the coding gene.
| Loss of PIGH mRNA could be explained by epigenetic control of gene transcription
To explore whether loss of PIGH mRNA expression in GPI-anchor negative B-ALL cells resulted from epigenetic down regulation, we analyzed the presence of two predominant types of histone modifications at the PIGH gene locus. We considered histone mark H3K4me3, of which presence is strongly correlated with actively transcribed genes, and histone mark H3K27me3, of which presence correlates with transcriptional gene silencing. 20 We performed H3K4me3 and H3K27me3 specific ChIP on DNA isolated from the GPI-anchor negative subcultures, using the GPI-anchor positive subcultures as references, followed by qPCR to quantify the relative presence of these histone marks at the PIGH gene locus. Almost complete loss of histone mark
H3K4me3 from the PIGH promoter region was found in both GPIanchor negative subcultures ( Figure 3A) . In contrast, presence of histone mark H3K27me3 was increased in both GPI-anchor negative subcultures, with the largest effect between the Leiden-ALL-BV subcultures ( Figure 3A ). These data imply that the PIGH gene in the GPIanchor negative subcultures was transcriptionally silenced. To test if PIGH promoter methylation is essential in retaining the GPI-anchor negative phenotype in B-ALL cells, we tested whether treatment of the GPI-anchor negative subcultures with the demethylating agent 5-aza would restore GPI-anchor expression. Gradual 
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| DISCUSSION
Durable remission in patients with B-ALL is often hampered by early disease relapse due to outgrowth of pre-existing subclones resistant to treatment. 2, 3 In this study, we showed that small GPI/CD52-negative B-cell populations were found already at diagnosis in the majority of patients with B-ALL at frequencies that are in line with previous reports. 10, 11 We showed that GPI-anchor negative B-cell populations were present in B-ALL patients carrying various cytoge- In PNH, lack of GPI-anchor expression is linked to a defect in the PIGA gene. We have previously shown that no mutations were present in PIGA in GPI-anchor negative B-ALL cells. 10 Here, we demonstrated that the GPI-anchor negative phenotype in B-ALL cells resulted from loss of PIGH mRNA expression. The PIGH gene is essential in GPIanchor synthesis as was previously shown in a CRISPR-Cas9 knockout screen. 12 Our study is the first to associate an anomaly related to the PIGH gene with a hematological disorder. Exploration of cancer genome databases did not yield an association between a genetic anomaly in PIGH and B-ALL (or any other malignancy), potentially as a result of the small contribution of the GPI-anchor negative cells to the total malignancy.
In contrast to the X-linked PIGA, PIGH is an autosomal gene located on chromosome 14q24.1, implying that two affected alleles are required for complete loss of PIGH mRNA expression. Molecular analysis revealed that epigenetic silencing rather than gene mutation or deletion resulted in loss of PIGH mRNA expression. Epigenetic silencing of tumor suppressor genes is a frequent event in cancer.
B-ALL cells may be particularly affected by this mechanism as they are arrested in an early stage of B-cell development at which major epigenetic changes take place to lock-in the lineage commitment and to initiate and maintain allelic exclusion of one of the immunoglobulin genes. 24, 25 Continued exposure to cellular processes triggering these epigenetic changes may lead to silencing of genes that are normally unaffected. In concordance, genome-wide de novo promoter DNA methylation was recently shown to be common in pediatric patients with B-ALL. 26, 27 Crosstalk between the various components of the epigenetic 
